Heart disease remains the leading cause of death in the United States, with the American Heart Association reporting over 940,000 deaths in 2022. The annual healthcare costs for cardiovascular conditions are forecasted to rise from $393 billion in 2020 to $1.4 trillion by 2050. Into this escalating crisis steps Cardio Diagnostics Holdings (NASDAQ: CDIO), a Chicago-based precision cardiovascular medicine company that combines artificial intelligence, epigenetics, and genetics to detect coronary heart disease, including forms that standard methods often miss, through a simple blood draw.
What distinguishes Cardio Diagnostics is its ability to identify coronary heart disease earlier and with high sensitivity, offering a defensible clinical position. The company's recent commercial and regulatory milestones further shape its investment thesis. According to the press release, the company's approach aims to solve a problem that traditional diagnostic tools have never fully addressed.
The scale of the problem is immense. Cardiovascular disease remains the leading cause of death across men, women, and most racial and ethnic groups, with one person dying every 34 seconds. Cardio Diagnostics leverages epigenetics—the study of changes in gene expression—and AI algorithms to analyze blood samples, potentially enabling earlier intervention and better outcomes.
For more information on Cardio Diagnostics, visit the company's newsroom at https://ibn.fm/CDIO. This press release was distributed by InvestorWire, a specialized communications platform within the Dynamic Brand Portfolio @IBN. InvestorWire provides advanced wire-grade press release syndication and enhanced press release services. For more details, see https://www.InvestorWire.com and the full terms of use and disclaimers at https://www.InvestorWire.com/Disclaimer.
